VCs Pull Back on Biotech Investments and Its FDA's Fault

Oct 7, 2011, 00:05 AM by Michael Croft

Wall Street Journal | Venture capitalists look to be steering their money away from biotech, a development that life science investors fear will push jobs and treatment overseas. The main reason for the shift? A Food and Drug Administration the investors says is dysfunctional, unpredictable, and risk-averse.

October 7, 2011 | Venture capitalists look to be steering their money away from biotech, a development that life science investors fear will push jobs and treatment overseas. The main reason for the shift? A Food and Drug Administration the investors says is dysfunctional, unpredictable, and risk-averse. Wall Street Journal